Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Tubach, Florence; Salmon, Dominique; Ravaud, Philippe; Allanore, Yannick; Goupille, Philippe; Bréban, Maxime; Pallot‐Prades, B.; Pouplin, Sophie; Sacchi, Alessandra; Chichemanian, R.-M.; Bretagne, Stéphane; Émilie, D; Lémann, Marc; Lorthololary, O.; Mariette, Xavier

doi:10.1002/art.24632

Public

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Published in Arthritis & Rheumatism • Jun 29, 2009

Authors:

Florence Tubach

Dominique Salmon

Philippe Ravaud

Abstract

OBJECTIVE: Tuberculosis (TB) is associated with anti-tumor necrosis factor (anti-TNF) monoclonal antibody (mAb) therapy, but whether this association is drug-specific remains a concern. Our objective was to describe cases of TB associated with anti-TNF mAb therapy, identify risk factors, and estimat...

Subject

Medicine

Adalimumab

Etanercept

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!